- Home
- FORA vs ANVS Comparison
FORA vs ANVS Comparison
Compare FORA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | ANVS |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 69.1M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FORA | ANVS |
|---|---|---|
| Price | $2.16 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 53.3K | ★ 1.2M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.00 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,256,919.00 | N/A |
| Revenue This Year | $8.44 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.13 | N/A |
| 52 Week Low | $1.64 | $1.54 |
| 52 Week High | $2.71 | $5.50 |
Technical Indicators
Market Signals| Indicator | FORA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 41.73 |
| Support Level | $2.05 | $1.79 |
| Resistance Level | $2.20 | $2.38 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 66.67 | 17.75 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.